Research Ready linked cohort for Metabolic Conditions (GLP-1 agonists)
As a leader in population genomics, we are actively building diverse germline clinico-genomic cohorts by fully integrating with health systems to implement precision medicine programs in a wide range of therapeutic areas. Our industry-leading WES platform (Exome+®) combined with consented, OMOP-standardized EHR data provides life science partners unparalleled access to comprehensive, scaled, longitudinal data for precision medicine development.
Driving drug discovery and development for Metabolic conditions with clinico-genomics
Leveraging our geographically extensive network of health system partners across the US, Helix has built a rapidly growing clinico-genomic cohort of thousands of GLP-1 agonist treated patients:
Linked Exome sequencing plus full EHR records from an ethnically diverse patient population
All of the lab measures included in the pivotal trials, such as HbA1c and blood glucose, matched with patient vitals and demographic information
Access to the Helix Research Network database in the form of yearly data licenses and/or translational research collaborations
